Pembrolizumab is an FDA approved monoclonal antibody directed against programmed cell death protein 1 (PD-1) and sold in the US. It initially received FDA accelerated approval for refractory, advanced melanoma in September 2014. Subsequently, it has received approval for the treatment of many other oncologic conditions, and many more are currently in clinical development.